Lung cancer remains a significant cause of mortality worldwide. While advances in therapy
continue to be made, the overall prognosis for patients diagnosed with lung cancer remains …

The two clinically validated and Food and Drug Administration approved lung cancer
predictive biomarkers (epidermal growth factor receptor mutations and anaplastic lymphoma …

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing
efforts for its early detection by screening populations at risk, the majority of lung cancer …

Patients at risk for lung cancer may have subclinical disease for years before presentation.
The diagnosis of this disease is primarily based on symptoms, and detection often occurs …

Lung carcinoma, especially in its most commonly diagnosed non-small cell histological form,
is a challenge to diagnose and treat worldwide, due to the prognosis in patients with this …

Lung cancer is diagnosed in more than 1.8 million people yearly and remains the leading
cause of cancer deaths in both developing and developed countries, with survival at 5 years …

Lung cancer has shown a decrease in incidence and mortality in recent decades; however,
it remains one of the cancers with the highest incidence and ranks first in cancerrelated …

The overall survival of patients with lung cancer is dismal despite extensive effort in
improvement of diagnosis and treatment. A better understanding of the multistep genetic and …

Lung cancer ranks top in both incidence and mortality in most part of the world. Scientists
strive to explore biomarkers and their possible role in the diagnosis, treatment and …

Context The analysis of molecular biomarkers in lung adenocarcinoma (ACA) is now a
central component of pathologic diagnosis and oncologic care. The identification of an …